Goldman Sachs Amends Silence Therapeutics Stake on Dec 29 Event
Ticker: SLNCF · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | SC 13G/A |
| Filed Date | Feb 12, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Goldman Sachs updated its Silence Therapeutics stake, watch for market reaction.**
AI Summary
Goldman Sachs Group Inc. filed an amended SC 13G/A on February 12, 2024, indicating a change in their beneficial ownership of Silence Therapeutics plc's American Depositary Shares (ADS). This filing, triggered by an event on December 29, 2023, updates their previous disclosure regarding their stake in the pharmaceutical company. This matters to investors because significant changes in institutional ownership, especially from a major player like Goldman Sachs, can signal shifts in market sentiment or investment strategy towards Silence Therapeutics plc.
Why It Matters
Changes in institutional ownership can influence stock price and reflect a major investor's updated view on the company's future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of ownership changes by a large institution and doesn't inherently signal high risk, but rather transparency.
Analyst Insight
An investor should monitor subsequent filings from Goldman Sachs regarding Silence Therapeutics plc to understand their evolving investment thesis and consider the implications for the stock.
Key Players & Entities
- Goldman Sachs Group Inc. (company) — the entity filing the SC 13G/A
- Silence Therapeutics plc (company) — the issuer of the securities
- December 29, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A
- American Depositary Shares (other) — the class of securities owned
Forward-Looking Statements
- Goldman Sachs will continue to hold a significant stake in Silence Therapeutics plc. (Goldman Sachs Group Inc.) — medium confidence, target: Q2 2024
- Silence Therapeutics plc's stock price may experience minor fluctuations following this disclosure. (Silence Therapeutics plc) — low confidence, target: February 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)*' sections.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is Goldman Sachs Group Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GOLDMAN SACHS GROUP INC' section.
What company's securities are the subject of this filing?
The securities are those of Silence Therapeutics plc, specifically 'American Depositary Shares, each representing 3 ordinary shares, nominal value 0.05 pound per share', as stated under the 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Silence Therapeutics plc' and '(Name of Issuer)' sections.
When was the event that triggered this filing?
The event that triggered this filing occurred on December 29, 2023, as specified in the '(Date of Event Which Requires Filing of this Statement)' section.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the American Depositary Shares of Silence Therapeutics plc is 82686Q101, as listed under the 'CUSIP Number' section.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 12, 2024 regarding Silence Therapeutics plc (SLNCF).